Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Great presentation in Oncology

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Nov 11, 2021 1:01pm

171 Views

Post# 34115681

RE:RE:RE:RE:RE:Great presentation in Oncology

Not listened to the presentation yet, but what you say below is impossible. Docetaxel is eliminated through the liver, by-products goes in the bile, and finally in the feces. Very little goes in the urine.

Wino115 wrote: My unscientific mind says this may not preclude one of the issues we list as to where the drugs going -- and that is down the toilet within an hour.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China